Communiqués Bavarian Nordic A/S

Actions

BAVA

DK0015998017

Temps réel estimé Cboe Europe Autres places de cotation 16:22:27 11/06/2024			Varia. 5j.	Varia. 1 janv.
172,4 ^DKK	-3,15 %		-4,93 %	-2,65 %

31/05	Bavarian Nordic dépose une demande de licence supplémentaire aux États-Unis pour son vaccin antivariolique et antivariolique du singe	MT
30/05	Bavarian Nordic obtient un financement de 6,5 millions de dollars pour le développement du vaccin Mpox chez les enfants	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine	31/05	GL
Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in Africa	30/05	GL
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise	22/05	GL
Bavarian Nordic A/S : Transactions in Connection with Share Buy Back Program and Termination of Share Buy Back Program	21/05	PU
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program	21/05	GL
EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian Nordic	21/05	GL
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations	08/05	GL
Bavarian Nordic A/S : Interim Results (Q1) as of 31 March 2024	08/05	PU
Bavarian Nordic Announces Interim Results for the First Three Months of 2024	08/05	GL
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such	07/05	GL
Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve	29/04	GL
Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate	29/04	GL
ExpreS2ion to receive approximately SEK 22.5 million dividend payment from AdaptVac ApS	23/04	AQ
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such	22/04	GL
Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/S	16/04	GL
Morris & Dickson is the First U.S. Distributor for Bavarian Nordic's JYNNEOS, the Only FDA-approved Mpox Vaccine	04/04	AQ
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.	02/04	GL
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.	02/04	AQ
Bavarian Nordic A/S : Notice Convening Annual General Meeting	21/03	PU
Bavarian Nordic A/S – Notice Convening Annual General Meeting	21/03	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Bavarian Nordic A/S

Actions

BAVA

DK0015998017

Communiqués

Filtres